Navigation Links
Cancer stem cells under the microscope at Albert Einstein College of Medicine symposium
Date:5/13/2014

May 13, 2014 (BRONX, NY) Healthy stem cells work to restore or repair the body's tissues, but cancer stem cells have a more nefarious mission: to spawn malignant tumors. Cancer stem cells were discovered a decade ago, but their origins and identity remain largely unknown.

Today, the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Albert Einstein College of Medicine of Yeshiva University hosted its second Stem Cell Symposium, focusing on cancer stem cells. Leading scientists from the U.S., Canada and Belgium discussed the latest advances in the field and highlighted the challenges of translating this knowledge into targeted cancer treatments.

"These exceptional scientists are pioneers in the field and have made enormous contributions to our understanding of the biology of stem cells and cancer," said Paul Frenette, M.D., director and chair of Einstein's Stem Cell Institute and professor of medicine and of cell biology. "Hopefully this symposium will spark productive dialogues and collaborations among the researchers who attend."

The presenters were:

  • "Cancer Stem Cells and Malignant Progression," Robert A. Weinberg, Ph.D., Daniel K. Daniel K. Ludwig Professor for Cancer Research Director, Ludwig Center of the Massachusetts Institute of Technology; Member, Whitehead Institute for Biomedical Research
  • "Towards Unification of Cancer Stem Cell and Clonal Evolution Models of Intratumoral Heterogeneity," John Dick, Ph.D., Canada Research Chair in Stem Cell Biology and senior scientist, Princess Margaret Cancer Center, University Health Network; professor of molecular genetics, University of Toronto
  • "Normal and Neoplastic Stem Cells," Irving L. Weissman, M.D., Director, Institute for Stem Cell Biology and Regenerative Medicine and Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine; Professor of Pathology and Developmental Biology, Stanford University School of Medicine
  • "Cell Fate Decisions During Tumor Formation," Leonard I. Zon, M.D., Grousbeck Professor of Pediatric Medicine, Director, Stem Cell Research Program, Howard Hughes Medical Institute/Boston Children's Hospital, Harvard Medical School
  • "Skin Stem Cells in Silence, Action and Cancer," Elaine Fuchs, Ph.D., Rebecca C. Lancefield Professor, Laboratory of Mammalian Cell Biology and Development, Howard Hughes Medical Institute/The Rockefeller University
  • "Mechanism Regulating Stemness in Skin Cancer," Cdric Blanpain, M.D., Ph.D., professor of stem cell and developmental biology, WELBIO, Interdisciplinary Research Institute, Universit Libre de Bruxelles
  • "Mouse Models of Malignant GBM: Cancer Stem Cells and Beyond," Luis F. Parada, Ph.D., professor and chairman, Diana K and Richard C. Strauss Distinguished Chair in Developmental Biology; Director, Kent Waldrep Foundation Center for Basic Neuroscience Research; Southwestern Ball Distinguished Chair in Nerve Regeneration Research, University of Texas Southwestern Medical Center


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Scientists from USC and NYU design a molecule that blocks cancer growth in mice
2. Researchers identify link between colon cancer and metabolism
3. JAX researchers identify potential therapeutic target for wound-healing and cancer
4. Henry Ford researchers identify genetic factors that may aid survival from brain cancer
5. University of Chicago chosen as a center for new cancer clinical trials network
6. Current guidelines underestimate US cervical cancer incidence and older womens risk
7. New method sneaks drugs into cancer cells before triggering release
8. Investigating the role of aging and poor nutrition on colon cancer: NIH awards Einstein $3.2 million grant
9. Ability to isolate and grow breast tissue stem cells could speed cancer research
10. Molecular tumor board helps in advanced cancer cases
11. Glutamine ratio is key ovarian cancer indicator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: